LAB icon

Standard BioTools

1.16 USD
-0.02
1.69%
At close Apr 29, 4:00 PM EDT
After hours
1.16
+0.00
0.00%
1 day
-1.69%
5 days
-8.66%
1 month
7.41%
3 months
-26.58%
6 months
-33.71%
Year to date
-33.71%
1 year
-53.23%
5 years
-52.26%
10 years
-97.08%
 

About: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Employees: 818

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

5% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 40

0% more funds holding

Funds holding: 140 [Q3] → 140 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 22

1.04% less ownership

Funds ownership: 75.54% [Q3] → 74.5% (-1.04%) [Q4]

10% less capital invested

Capital invested by funds: $541M [Q3] → $485M (-$55.7M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

93% less call options, than puts

Call options by funds: $12K | Put options by funds: $178K

Research analyst outlook

We haven’t received any recent analyst ratings for LAB.

Financial journalist opinion

Neutral
GlobeNewsWire
5 days ago
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025.
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
Neutral
GlobeNewsWire
1 week ago
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
Neutral
GlobeNewsWire
2 months ago
Standard BioTools to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences:
Standard BioTools to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
2 months ago
Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript
Standard BioTools Inc. (NASDAQ:LAB ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Kyle Boucher - TD Cowen Paul Knight - KeyBanc Operator Good day, everyone, and welcome to Standard BioTools' Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, this conference is being recorded.
Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 months ago
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024.
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
2 months ago
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close.
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025
Neutral
GlobeNewsWire
3 months ago
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m.
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
Neutral
GlobeNewsWire
4 months ago
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P.
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Neutral
GlobeNewsWire
5 months ago
Standard BioTools Appoints Alex Kim as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization.
Standard BioTools Appoints Alex Kim as Chief Financial Officer
Neutral
GlobeNewsWire
5 months ago
Standard BioTools to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12 th , 2024 President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m.
Standard BioTools to Participate in Upcoming Investor Conferences
Charts implemented using Lightweight Charts™